Table 3

Change in clinical status before and after switching
Before switching After switching
OLZ-RIS (n=162) RIS-OLZ (n=136) OLZ-RIS (n=162) RIS-OLZ (n=136)
Change in CGI-overall score from baselinea(Mean ± SD) −0.75±1.05 −0.71±1.20 −1.15±1.12 −1.46±1.29
EPSb(%) 15.2 28.4 15.2 9.0
Loss of libidob(%) 28.8 37.8 31.3 26.7
Impotence/sexual dysfunctionb(%) 18.9 29.3 22.0 19.6
Amenorrhoea/galactorrheaa(%) 12.0 12.6 17.7 5.9
Change in weight (kg) from baselinec(Mean ± SD) 3.14±6.05 1.43±4.21 4.11±8.39 1.95±8.90

aThe difference between before and after switching was significant in both groups (p<0.05).

bThe difference between before and after switching was significant only in patients who switched to olanzapine (i.e., the RIS-OLZ group).

cThe difference between before and after switching was not significant in either group.

OLZ-RIS: Patients who switched from olanzapine to risperidone.

RIS-OLZ: Patients who switched from risperidone to olanzapine.

EPS: Extrapyramidal Symptom.

Hong et al.

Hong et al. BMC Psychiatry 2012 12:218   doi:10.1186/1471-244X-12-218

Open Data